The IMMP1L Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung epithelial carcinoma cell line, featuring disruption of the IMMP1L gene. This loss-of-function model is generated without single-cell cloning, thereby preserving population heterogeneity and reducing clonal artifacts. It enables robust investigation of IMMP1L-dependent mitochondrial biology in a cancer-relevant context, suitable for assays that demand a genetically diverse knockout pool.
The A-549 host cell line is a widely utilized model of human alveolar basal epithelial adenocarcinoma, originally isolated from a 58-year-old male lung adenocarcinoma patient. These cells retain hallmark oncogenic mutations and exhibit epithelial morphology with adherent growth, facilitating experimental manipulation. A-549 cells are extensively employed in cancer metabolism, drug screening, and apoptosis research, providing a biologically appropriate platform for studying the impact of mitochondrial gene disruption on tumor cell physiology.
IMMP1L encodes a mitochondrial inner membrane peptidase that processes imported precursor proteins, maintaining mitochondrial proteostasis and respiratory chain function. It operates within the mitochondrial disulfide relay system, interacting with CHCHD4 (Mia40) and ALR (GFER) to mature intermembrane space proteins, including cytochrome c and OXPHOS subunits. Upstream regulators PGC-1??, NRF1, and TFAM transcriptionally control IMMP1L expression, while downstream targets encompass CHCHD4 and electron transport chain components. IMMP1L thus connects mitochondrial import machinery (TIM23 complex) to oxidative metabolism and apoptosis signaling, with its disruption expected to impair protein maturation and apoptotic regulation.
In A-549 lung adenocarcinoma cells, elimination of IMMP1L likely disrupts mitochondrial protein processing, leading to defective oxidative phosphorylation and altered apoptotic thresholds. This recapitulates aspects of mitochondrial disorders and unveils potential metabolic liabilities in cancer. The polyclonal knockout format permits assessment of phenotypic variability and average effects without clonal bias, facilitating studies on how IMMP1L influences metabolic reprogramming, stress responses, and chemosensitivity in lung cancer models.
This product is suited for diverse applications including mitochondrial biology, cancer metabolism, and apoptosis research. Representative assays include Western blotting for IMMP1L, RT-qPCR for transcript quantification, Seahorse-based metabolic flux analysis, caspase-3/7 activity measurements, flow cytometry for mitochondrial mass, and immunofluorescence imaging of mitochondrial morphology. These tools enable detailed dissection of IMMP1L??s role in energy metabolism and cell death pathways. For further technical details, please contact Ascent Research.
